RBC reiterates Medicis at outperform

Medicis Pharmaceutical Corp. analyst Ken Trbovich was reiterated at outperform, above average risk, and maintained at a $35 price target. IMS Health data for the week ended Sept. 22 shows 7,475 Solodyn prescriptions. Total oral acne prescriptions continue to show growth despite a Dynacin decline. Together with the old Dynacin brand, for which prescriptions were down slightly from 1,995 to 1,920, the company's acne franchise is up 93% from the comparable week last year and about 3% from the prior week. Solodyn, tracking at $140 million run-rate 13 weeks into its launch, still holds potential to exceed $175 million run-rate. Shares of the Scottsdale, Ariz.-based specialty pharmaceutical company were up 6 cents, or 0.19%, at $32.41. (NYSE: MRX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.